Circumvention of TKI resistance with HDAC inhibitors in lung cancer

被引：0
|
作者：
Yano, Seiji [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 9201192, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JS1-5
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [41] ImatinibDevelopment of tyrosine kinase inhibitors (TKI) resistance: case report
    Reactions Weekly, 2016, 1585 (1) : 141 - 141
  • [42] HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing
    Liu, Jie
    Wang, Wei
    Wang, Kunkun
    Liu, Wenjing
    Zhao, Yanqiu
    Han, Xiao
    Wang, Lin
    Jiang, Bing-Hua
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [43] Apatinib Combined with EGFR - TKI in Treating Advanced Non-Small Cell Lung Cancer with EGFR - TKI Resistance (Data Updated)
    Tian, R.
    Song, X.
    Guo, Y.
    Zhang, X.
    Guo, W.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S571 - S571
  • [44] Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer
    To, Kenneth K. W.
    Poon, Daniel C.
    Wei, Yuming
    Wang, Fang
    Lin, Ge
    Fu, Li-wu
    DATA IN BRIEF, 2016, 7 : 437 - 444
  • [45] Circumvention of drug resistance in cancer cells by a new fluoropyrimidine analogue
    Kim, SH
    Kang, CD
    Chung, BS
    Kim, JC
    EXPERIMENTAL AND MOLECULAR MEDICINE, 1996, 28 (03): : 119 - 123
  • [46] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
    Zhou, Yinxue
    Wu, Tingyu
    Sun, Jiaxing
    Bi, Huanhuan
    Xiao, Yuting
    Shao, Yanmei
    Han, Weizhong
    Wang, Hongmei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4327 - 4343
  • [48] HDAC inhibitors as a means to allow for metabolic targeting in non-small cell lung cancer?
    Gray, Steven G.
    Davies, Anthon M.
    O'Byrne, Kenneth J.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S796 - S796
  • [49] Reduction of Drug Resistance Through Calcium Control in EGFR TKI Resistant Lung Cancer Cells
    Yang, S.
    Kim, M.
    Kim, S.
    Kim, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S562 - S562
  • [50] CIRCUMVENTION OF DRUG-RESISTANCE IN HUMAN NON-SMALL CELL LUNG-CANCER INVITRO BY VERAPAMIL
    MERRY, S
    COURTNEY, ER
    FETHERSTON, CA
    KAYE, SB
    FRESHNEY, RI
    BRITISH JOURNAL OF CANCER, 1987, 56 (04) : 401 - 405
12345